Table 7.
Treatment predictors (Use of number of drugs of each WHO group) of treatment success versus death and treatment failure among children and adolescents treated for rifampicin-resistant tuberculosis stratified by age
| Use of number of drugs of each WHO group | Treatment success versus unfavourable outcomes (death/treatment failure) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age < 5 years | Age 5 to <10 years | Age 10 to <15 years | Age 15–19 years | |||||||||||||
| Univariable logistic regression models | Multivariable logistic regression modela | Univariable logistic regression models | Multivariable logistic regression modela | Univariable logistic regression models | Multivariable logistic regression modela | Univariable logistic regression models | Multivariable logistic regression modela | |||||||||
| Crude OR (95% CI) | p-value | aOR (95% CI) | p-value | Crude OR (95% CI) | p-value | aOR (95% CI) | p-value | Crude OR (95% CI) | p-value | aOR (95% CI) | p-value | Crude OR (95% CI) | p-value | aOR (95% CI) | p-value | |
| Number of drugs group A b | ||||||||||||||||
| 1 | 1.33 (0.66–2.68) | 0.42 | 0.93 (0.43–2.00) | 0.85 | 0.89 (0.51–1.56) | 0.69 | 0.89 (0.48–1.62) | 0.70 | 1.70 (1.2–2.40) | 0.0027 | 1.32 (0.92–1.89) | 0.13 | 1.3 (1.08–1.56) | 0.0066 | 0.95 (0.77–1.16) | 0.62 |
| 2 | 1.08 (0.4–2.9) | 0.88 | 0.73 (0.25–2.10) | 0.55 | 1.62 (0.65–4.1) | 0.30 | 1.03 (0.37–2.87) | 0.96 | 1.11 (0.67–1.83) | 0.69 | 0.94 (0.57–1.67) | 0.92 | 1.73 (1.29–2.32) | 0.00027 | 1.66 (1.21–2.28) | 0.0016 |
| 3 | 0.28 (0.07–1.14) | 0.076 | 0.42 (0.09–2.02) | 0.28 | 3.12 (0.40–24.4) | 0.28 | 2.23 (0.26–18.71) | 0.46 | 3.03 (1.55–5.94) | 0.0013 | 2.81 (1.39–5.70) | 0.0040 | 2.21 (1.65–2.96) | <0.0001 | 2.36 (1.72–3.23) | <0.0001 |
| Number of drugs group B c | ||||||||||||||||
| 1 | 1.68 (0.78–3.62) | 0.19 | 1.78 (0.78–4.04) | 0.17 | 1.11 (0.51–2.43) | 0.80 | 1.26 (0.57–2.80) | 0.56 | 1.34 (0.74–2.45) | 0.34 | 1.3 (0.69–2.45) | 0.41 | 1.55 (1.08–2.22) | 0.016 | 1.18 (0.80–1.75) | 0.41 |
| 2 | 1.83 (0.67–4.97) | 0.24 | 1.47 (0.50–4.29) | 0.48 | 2.06 (0.73–5.84) | 1.74 | 2.17 (0.71–6.66) | 0.17 | 0.61 (0.33–1.16) | 0.13 | 0.64 (0.32–1.26) | 0.19 | 0.67 (0.47–0.98) | 0.040 | 0.48 (0.32–0.73) | 0.00052 |
| Number of drugs group C d | ||||||||||||||||
| 2 | 0.95 (0.2–4.5) | 0.95 | 0.95 (0.18–4.98) | 0.95 | 0.64 (0.14–2.92) | 0.57 | 0.73 (0.15–3.56) | 0.70 | 1.2 (0.65–2.25) | 0.555 | 1.27 (0.64–2.51) | 0.49 | 0.96 (0.7–1.31) | 0.80 | 1.09 (0.77–1.54) | 0.62 |
| 3 | 0.96 (0.21–4.3) | 0.96 | 0.78 (0.15–3.95) | 0.76 | 0.82 (0.19–3.63) | 0.79 | 1.21 (0.25–5.79) | 0.81 | 1.73 (0.94–3.17) | 0.078 | 1.47 (0.75–2.88) | 0.26 | 1.32 (0.97–1.79) | 0.075 | 1.08 (0.77–1.50) | 0.67 |
| 4 or more | 1.1 (0.24–5.11) | 0.90 | 0.86 (0.16–4.58) | 0.86 | 0.79 (0.18–3.51) | 0.75 | 1.15 (0.24–5.66) | 0.86 | 1.79 (0.96–3.32) | 0.065 | 1.39 (0.69–2.76) | 0.36 | 1.73 (1.27–2.36) | 0.00055 | 1.24 (0.88–1.74) | 0.22 |
Multivariable model, including all predictors listed (Number of drugs group A, Number of drugs group B, Number of drugs group C), and adjusted for the following baseline clinical characteristics: age, sex, HIV status, history of any past tuberculosis treatment, having pulmonary disease and smear +.
Use of no drugs from group A, reference for predictor Number of drugs group A.
Use of no drugs from group B, reference for predictor Number of drugs group B.
Use of one or no drugs from group C, reference for predictor Number of drugs group C.
Abbreviations: aOR, adjusted odds ratio. CI, confidence interval.